Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AIMM Therapeutics logo — Crafting powerful antibody treatments sourced from the immun...

AIMM Therapeutics

Crafting powerful antibody treatments sourced from the immune systems of recovered patients and immunized animals to combat cancer and infectious diseases.

Founded 2004 Series Unknown Biotechnology

General Information

Company Name AIMM Therapeutics
Founded Year 2004
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when AIMM Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AIMM Therapeutics

AIMM Therapeutics is a biotechnology startup founded in 2004, dedicated to crafting powerful antibody treatments for combatting cancer and infectious diseases. The company sources these treatments from the immune systems of recovered patients and immunized animals. AIMM Therapeutics develops antibody-based treatments by discovering the most effective antibodies against cancer and infectious diseases that are obtained from individuals who have overcome disease or from immunized animals. The startup received a Venture Round investment on 03 June 2009 from the Life Sciences Fund Amsterdam.

Taxonomy: antibody treatments, immune system, recovered patients, cancer, infectious diseases, AIMM Therapeutics, antibody-based treatments, effective antibodies, disease treatment, immunized animals, immunotherapy, biotech innovation, medical research, drug development, therapeutic antibodies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1
Investor
03 Jun 2009

Latest News

View All
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Colle... — Dutchnews.nl
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
Dutchnews.nl Jan 26, 2021

AIMM Therapeutics Alternatives & Competitors

AIMM Therapeutics vs
AbD Serotec - a Bio-Rad Company
AbD Serotec - a Bio-Rad Company

This is our old page and we no longer post updates here. For the latest news please follow Bio-Rad A...

63 employees
Biotechnology, Industrial
AIMM Therapeutics vs
Mabqi
Mabqi France

Your key partner for breakthrough antibody discovery

26 employees
Biotechnology
AIMM Therapeutics vs
Specifica, an IQVIA business
Specifica, an IQVIA business United States

Antibody discovery campaigns, antibody optimization, and tailored antibody libraries

28 employees

FAQ About AIMM Therapeutics

Crafting powerful antibody treatments sourced from the immune systems of recovered patients and immunized animals to combat cancer and infectious diseases.
AIMM Therapeutics was founded in 2004.
AIMM Therapeutics operates in the following industries: Biotechnology.
AIMM Therapeutics has completed 1 funding round. The latest funding stage is Series Unknown.
Top alternatives and competitors to AIMM Therapeutics include AbD Serotec - a Bio-Rad Company, Mabqi, Specifica, an IQVIA business, Klus Pharma Inc., Capralogics Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AIMM Therapeutics and AbD Serotec - a Bio-Rad Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AIMM Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy